Heghine Khachatryan: The Future of Anticoagulation Beyond DOACs
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, reposted from JTH on LinkedIn, about a recent article by Holly Dobbing et al, adding:
”Beyond DOACs: The Future of Anticoagulation
The recently highlighted article in the Journal of Thrombosis and Haemostasis explores novel and experimental anticoagulant strategies beyond current DOACs — a rapidly evolving field with profound clinical implications.
While direct oral anticoagulants (DOACs) have transformed thrombosis management, significant unmet needs remain:
- Patients with high bleeding risk
- Mechanical heart valves
- Advanced renal impairment
- Antiphospholipid syndrome
- Recurrent thrombosis despite standard therapy
Emerging therapeutic targets such as Factor XI and XIa inhibitors, RNA-based approaches, and next-generation selective pathway modulation aim to provide:
- Effective thrombosis prevention
- Reduced bleeding liability
- More precise coagulation control
For clinicians working in thrombosis and hemostasis, this represents a paradigm shift — moving from broad anticoagulation toward mechanism-refined, safer antithrombotic strategies.
As we continue strengthening thrombosis care systems in Armenia and globally, staying aligned with these innovations is essential for advancing patient safety and equity in treatment access.
Highly recommended reading for hematologists, cardiologists, and clinical researchers.”
Quoting Journal of Thrombosis and Haemostasis (JTH)‘s post:
”Novel and Experimental Anticoagulant Strategies Beyond Current DOACs
Emerging anticoagulation strategies explore contact pathway inhibition, fibrin targeting, and natural anticoagulant pathway enhancement to address DOAC limitations, promising safer thrombosis treatment with reduced bleeding risks for cardiovascular disease management.”
Title: Novel and experimental anticoagulant strategies beyond current direct oral anticoagulants
Authors: Holly Dobbing, Katherine L. Webb, Robert Ariëns
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session
-
Aug 30, 2026, 17:02David McGlasson: A 2020 Article Reaches 8,000 Reads
-
Aug 30, 2026, 16:18Tushar Namdeo: Platelets in Different Diseases
-
Aug 30, 2026, 16:16Fatima Zafar: Anaemia – Why This “Common” Condition Should Never Be Ignored
-
Aug 30, 2026, 16:13Umeshkumar C.: Evaluating Scoring Systems and Biomarkers for DIC in Critically Ill Patients